CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
riluzoledrug
Likely dose
riluzole 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00866840
NCT00866840Phase 2Completed
CompareCT.gov

A Phase II Trial of Riluzole in Patients With Advanced Melanoma

Rutgers, The State University of New Jersey·interventional·Posted Mar 23, 2009·Updated Jan 19, 2024

In Brief

A Phase 2 clinical trial evaluating riluzole for Melanoma (Skin). Completed, enrolled 13 participants across 1 site.

Detailed Summary

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma (Skin)
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.3 years ago

Interventions

riluzoledrug

100 mg orally twice daily